Tauriga Sciences Inc. confirms that it is on the right track for a


The company’s current operating quarter is its 2sd Fiscal quarter 2022 (Period: July 1, 2021 – September 30, 2021)

NEW YORK, NY, August 03, 2021 (GLOBE NEWSWIRE) – via NewMediaWire – Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a diverse New York-based life sciences company, today confirmed that it is on track to a strong quarter in its retail business. The Company’s current operating quarter is its 2sd Fiscal quarter 2022 (Period: July 1, 2021 – September 30, 2021). During the month of July 2021, the company saw an acceleration in demand and interest for its improved products and product lines as well as its innovative and newly introduced product offerings. The Company has also succeeded in integrating cost reduction measures into its manufacturing processes without any compromise in quality.

For the month of July 2021: net income exceeded $ 60,000

The company’s enhanced Tauri-Gum â„¢ product line (its flagship brand) has been well received by existing e-commerce customers as well as potential retail customers (of all sizes). The Company is confident in the competitiveness of its established wholesale prices, which preserve strong “embedded” gross margins for expected future revenue growth.

In addition – The Company is delighted with the commercial launch of its innovative Delta 8 THC chewing gum (10 mg); Evergreen mint flavored version of Tauri-Gum â„¢.

With inventory now available for all of its products and enhanced product lines, the Company will focus on significant revenue growth and continued acquisition of new customers. There are many exciting corporate initiatives currently underway and the Company looks forward to keeping its shareholders informed as significant progress is made.

ABOUT TAURIGA SCIENCES INC.

Tauriga Sciences, Inc. (TAUG) is a diverse and income-generating life sciences company engaged in several major business activities and initiatives. The Company manufactures and distributes several proprietary retail products and product lines, primarily focused on the cannabidiol (“CBD”) and cannabigerol (“CBG”) edibles market segment. The main product line, under the Tauri-Gum â„¢ brand, consists of an exclusive supplement of certified kosher, halal and vegan chewing gum (Tauri-Gum â„¢ aromas infused with CBD: mint, blood orange, pomegranate), ( infused with CBG Tauri-Gum â„¢ flavors: Peach-Lemon, Blackcurrant), (Tauri-Gum â„¢ flavor infused with vitamin C + zinc: Pear Bellini), (Tauri-Gum â„¢ flavor infused with caffeine: Cherry Lime Rickey), & ( Tauri infused with vitamin D3 – Gum â„¢ flavor: Golden Raspberry). The Company’s marketing strategy consists of a broad range of retail customers, distributors and a rapidly growing e-commerce business segment (e-commerce website: www.taurigum.com). Please visit our corporate website, for more information, as well as inquiries, at http://www.tauriga.com

Its ongoing pharmaceutical development initiative is complementary to the Company’s retail activities. This concerns the development of a proposed pharmaceutical grade version of Tauri-Gum â„¢, for the regulation of nausea (specifically designed for the following indication: patients undergoing chemotherapy treatment in progress). On March 22, 2021, the Company announced that it had converted its provisional patent application in the United States (filed March 17, 2020) to a non-provisional patent application in the United States. The patent, filed with the USPTO, is entitled “DRUG CBD COMPOSITIONS, METHODS OF MANUFACTURE AND METHODS OF TREATMENT”. On December 18, 2020, the Company announced that it had entered into a Master Services Agreement with CSTI to lead the Company’s clinical development efforts.

The company is headquartered in Wappingers Falls, New York. In addition, the Company operates two full-time e-commerce distribution centers: one located in Montgomery, Texas, and the other in Brooklyn, New York.

DISCLAIMER – Forward-looking statements

This press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995, which represent the opinions and assumptions of management regarding future events. These forward-looking statements are often indicated using words such as “may”, “will”, “expects”, “anticipates”, “believes”, “hopes”, “believes” or plans, and may include statements regarding business objectives such as as well as the achievement of certain business goals and milestones. Forward-looking statements are based on current circumstances and the current beliefs of management regarding events that have not occurred, which may not occur, or which may occur with consequences or a timeline different from those currently believed or anticipated. . Actual results may differ materially from those expressed in forward-looking statements due to known and unknown risks and uncertainties, such as general economic and business conditions, the ability to successfully develop and market products, habits and consumption levels of consumers and businesses, the ability to complete acquisition and licensing transactions, exchange rate fluctuations and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in more detail in the “Risk Factors” section of Tauriga’s Form 10-K and other periodic filings made from time to time with the Securities and Exchange Commission. These forward-looking statements are made only as of the date of this press release, and Tauriga assumes no obligation to update any forward-looking statements to reflect subsequent events or circumstances. You should not place undue reliance on these forward-looking statements.

Contact:

Tauriga Sciences, Inc.

4 Cour de Nancy, office 4

Wappingers Falls, NY 12590

Chief Executive Officer

Mr. Seth M. Shaw

Email: [email protected]

cell # (917) 796 9926

Company Instagram: @taurigum

Personal Instagram: @ sethsms47

Twitter: @SethMshaw

Company website: www.tauriga.com

E-commerce website: www.tauricum.com


Comments are closed.